二甲双胍联合沙格列汀对早期2型糖尿病的治疗效果

Efficacy of Metformin Combined with Saxagliptin in the Treatment of Early Type 2 Diabetes

目的 分析二甲双胍联合沙格列汀对早期2型糖尿病(Type 2-Diabetes Mellitus, T2DM)的治疗效果。方法选取2021年7月—2023年2月南平市第二医院收治的98例早期T2DM患者为研究对象,应用随机对照表法分为对照组和观察组,各49例。对照组予以二甲双胍治疗,观察组予以二甲双胍联合沙格列汀治疗。通过观察及跟踪,对比两组血糖控制情况、糖代谢相关指标及不良反应。结果 治疗前,两组空腹血糖(Fasting Blood Glucose, FBG)、餐后2 h血糖(2-hour Postprandial Blood Glucose, 2 hPG)、糖化血红蛋白(Glycosylated Hemoglobin, HbA1c)、空腹胰岛素、胰岛素抵抗指数(Insulin Resistance Index, HOMA-IR)等血糖及糖代谢指标比较,差异无统计学意义(P均>0.05)。治疗后,两组各项血糖水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P均<0.05)。治疗后,两组HbA1c、HOMA-IR糖代谢指标低于治疗前,且观察组低于对照组,空腹胰岛素指标高于治疗前,且观察组高于对照组,差异有统计学意义(P均<0.05)。治疗过程中,观察组出现恶心呕吐、乏力、低血糖等不良反应发生率为12.24%,与对照组的16.33%比较,差异无统计学意义(P>0.05)。结论 二甲双胍联合沙格列汀治疗早期T2DM,可改善血糖值及相关糖代谢指标,无显著不良反应,临床意义显著。

Objective To investigate the efficacy of metformin combined with saxagliptin in the treatment of early type 2 diabetes mellitus(T2DM).Methods 98 patients with early T2DM admitted to the Second Hospital of Nanping City from July 2021 to February 2023 were selected as the study objects,and were divided into control group and observa-tion group by random comparison table method,with 49 cases in each group.The control group was treated with met-formin,and the observation group was treated with metformin combined with saxagliptin.Through observation and follow-up,blood glucose control,glucose metabolism related indexes and adverse reactions were compared between the two groups.Results Before treatment,there was no statistically significant difference in blood glucose and glucose metabolism indicators such as fasting blood glucose(FBG),2-hour postprandial blood glucose(2 hPG),glycated hemo-globin(HbA1c),fasting insulin,insulin resistance index(HOMA-IR)between the two groups(all P>0.05).After treat-ment,the average blood glucose levels in both groups were lower than before treatment,and the observation group was lower than the control group,and the difference was statistically significant(all P<0.05).After treatment,the HbA1c and HOMA-IR glucose metabolism indicators in both groups were lower than before treatment,and the observation group was lower than the control group,the fasting insulin indicators were higher than before treatment,and the obser-vation group was higher than the control group,and the differences were statistically significant(all P<0.05).During the treatment process,the incidence of adverse reactions such as nausea,vomiting,fatigue,and hypoglycemia in the observation group was 12.24%,compared with 16.33%in the control group,and the difference was not statistically sig-nificant(P>0.05).Conclusion The combination of metformin and salagliptin in the treatment of early T2DM can im-prove blood glucose levels and related glucose metabolism indicators,with no significant adverse reactions and signifi-cant clinical significance.